FIELD: biotechnology.
SUBSTANCE: antibody is proposed that binds to a complex of human GARP and human TGF-β1. Polynucleotides encoding the specified antibody, an expression vector, a host cell, an acellular expression system, and a method for producing an antibody are also proposed.
EFFECT: invention provides for high affinity and capability of inhibiting the release of active TGF-β from regulatory T-cells, as well as increased stability of an antibody due to its resistance to deamidation, isomerization and oxidation.
13 cl, 20 dwg, 43 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION CANCER THERAPIES TARGETTING CD38 AND TGF-BETA | 2019 |
|
RU2808632C2 |
| IL2 AND MUTANT TNF IMMUNOCONJUGATES | 2017 |
|
RU2758139C2 |
| ANTIBODIES TARGETING BONE | 2018 |
|
RU2801206C2 |
| FUSED PROTEIN CONTAINING TGF-BETA RECEPTOR, AND ITS PHARMACEUTICAL USE | 2018 |
|
RU2776204C1 |
| ANTIBODIES WHICH BIND TO SORTILIN AND INHIBIT THE BINDING OF PROGRANULIN | 2016 |
|
RU2735639C2 |
| ANTI-IL-22R-ANTIBODIES | 2017 |
|
RU2758721C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| ISOLATED HUMAN CD45RC ANTIBODY, NUCLEIC ACID, EXPRESSION VECTOR, CELL, PHARMACEUTICAL COMPOSITION, USE THEREOF, IN VITRO METHOD OF DETECTING hCD45RC | 2019 |
|
RU2826421C2 |
| PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION | 2019 |
|
RU2791683C2 |
